Phathom officer surrenders 460 shares for tax withholding

Phathom’s principal accounting officer surrendered shares to cover tax withholding on restricted stock units while retaining significant direct and 401(k) holdings.

Rhea-AI Filing Summary

Phathom Pharmaceuticals, Inc. (PHAT) reported that Principal Accounting Officer Robert Charles Breedlove surrendered shares on September 3, 2026 to cover taxes on equity compensation. He delivered 460 shares of common stock, valued at $9.05 per share, to satisfy the company’s tax withholding obligation on vested restricted stock units.

After this withholding event, he continued to hold 59,465 shares of Phathom common stock directly, plus an additional 8,191.78 shares held indirectly through a 401(k) plan. No transactions were reported as being made under a Rule 10b5-1 trading plan.

Insider Trade Summary

Tax Withholding: 460 shares

Tax Withholding 2 txns

Insider Breedlove Robert Charles

Role Principal Accounting Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock F1	460	$9.05	$4K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 59,465 shares (Direct); Common Stock — 8,191.78 shares (Indirect, By 401(k))

Footnotes (1)

1. F1. Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

Key Figures

Shares surrendered for tax withholding: 460 shares Per-share value of surrendered shares: $9.05 per share Direct common stock holdings after transaction: 59,465 shares +1 more

4 metrics

Shares surrendered for tax withholding 460 shares Common stock delivered on September 3, 2026 to satisfy tax withholding on restricted stock units

Per-share value of surrendered shares $9.05 per share Valuation used for the 460 shares surrendered for tax withholding

Direct common stock holdings after transaction 59,465 shares Direct Phathom common stock position for Robert Charles Breedlove after the September 3, 2026 event

Indirect 401(k) holdings 8,191.78 shares Phathom common stock held indirectly through a 401(k) plan as reported in the filing

Key Terms

restricted stock units, tax withholding obligation, 401(k)

3 terms

restricted stock units financial

"shares underlying the restricted stock units that were surrendered"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligation financial

"in satisfaction of the Issuer's tax withholding obligation"

401(k) financial

"By 401(k)"

A 401(k) is a type of retirement savings plan offered by employers that allows workers to set aside a portion of their paycheck before taxes are taken out. The money saved in a 401(k) can grow over time through investments, helping individuals build funds for their future retirement. It matters to investors because it provides a tax-advantaged way to save and invest for long-term financial security.

FAQ

What insider transaction did Phathom Pharmaceuticals (PHAT) report for Robert Charles Breedlove?

On September 3, 2026, Principal Accounting Officer Robert Charles Breedlove surrendered 460 shares of Phathom common stock to the company to satisfy its tax withholding obligation related to vested restricted stock units.

At what price were the surrendered PHAT shares valued in this Form 4?

The 460 shares of Phathom common stock surrendered for tax withholding were valued at $9.05 per share, according to the reported transaction price on September 3, 2026.

How many PHAT shares does Robert Charles Breedlove hold directly after this transaction?

Following the September 3, 2026 tax-withholding surrender, Robert Charles Breedlove held 59,465 shares of Phathom Pharmaceuticals common stock in a direct ownership capacity.

What are Robert Charles Breedlove’s indirect PHAT holdings through his 401(k) plan?

In addition to his direct holdings, the filing reports that Robert Charles Breedlove held 8,191.78 shares of Phathom common stock indirectly through a 401(k) plan as of the transaction date.

Was the reported PHAT insider transaction made under a Rule 10b5-1 trading plan?

No. The filing does not indicate that the September 3, 2026 tax-withholding transaction by Robert Charles Breedlove was made under a Rule 10b5-1 or other pre-arranged trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/08/2026 - 04:31 PM Accepted by SEC EDGAR 09/08/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Breedlove Robert Charles

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2026		F(1)		460	D	$9.05	59,465	D
Common Stock								8,191.78	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying the restricted stock units that were surrendered by the reporting person to the Issuer in satisfaction of the Issuer's tax withholding obligation.

	/s/ Robert Charles Breedlove	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)